2016 Q3 Form 10-Q Financial Statement

#000143774916041758 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q3
Revenue $3.438M $1.200M
YoY Change 186.5% 700.0%
Cost Of Revenue $566.0K $269.0K
YoY Change 110.41% 572.5%
Gross Profit $2.872M $931.0K
YoY Change 208.49% 746.36%
Gross Profit Margin 83.54% 77.58%
Selling, General & Admin $4.929M $4.716M
YoY Change 4.52% 146.91%
% of Gross Profit 171.62% 506.55%
Research & Development $4.000K $1.563M
YoY Change -99.74% -32.34%
% of Gross Profit 0.14% 167.88%
Depreciation & Amortization $31.00K $41.00K
YoY Change -24.39% -18.0%
% of Gross Profit 1.08% 4.4%
Operating Expenses $4.933M $6.279M
YoY Change -21.44% 48.44%
Operating Profit -$2.061M -$5.348M
YoY Change -61.46% 29.81%
Interest Expense -$1.670M $140.0K
YoY Change -1292.86% -240.0%
% of Operating Profit
Other Income/Expense, Net -$4.000K -$31.00K
YoY Change -87.1%
Pretax Income -$3.736M -$5.240M
YoY Change -28.7% 24.17%
Income Tax $2.000K
% Of Pretax Income
Net Earnings -$3.736M -$5.242M
YoY Change -28.73% 24.22%
Net Earnings / Revenue -108.67% -436.83%
Basic Earnings Per Share
Diluted Earnings Per Share -$342.8K -$1.753M
COMMON SHARES
Basic Shares Outstanding 10.91M 2.957B
Diluted Shares Outstanding 10.91M 2.957B

Balance Sheet

Concept 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.430M $3.380M
YoY Change 178.99% -63.02%
Cash & Equivalents $9.430M $3.383M
Short-Term Investments
Other Short-Term Assets $286.0K $670.0K
YoY Change -57.31% 31.37%
Inventory $1.084M $1.580M
Prepaid Expenses $1.827M
Receivables $2.080M $540.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $14.42M $6.180M
YoY Change 133.33% -40.69%
LONG-TERM ASSETS
Property, Plant & Equipment $282.0K $360.0K
YoY Change -21.67% -25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $439.0K $150.0K
YoY Change 192.67% 0.0%
Total Long-Term Assets $721.0K $510.0K
YoY Change 41.37% -17.74%
TOTAL ASSETS
Total Short-Term Assets $14.42M $6.180M
Total Long-Term Assets $721.0K $510.0K
Total Assets $15.14M $6.690M
YoY Change 126.32% -39.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $387.0K $2.870M
YoY Change -86.52% 211.96%
Accrued Expenses $1.880M $1.010M
YoY Change 86.14% -14.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.728M $4.250M
YoY Change -12.28% 80.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $198.0K $2.210M
YoY Change -91.04% -26.33%
Total Long-Term Liabilities $198.0K $2.210M
YoY Change -91.04% -26.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.728M $4.250M
Total Long-Term Liabilities $198.0K $2.210M
Total Liabilities $8.423M $6.460M
YoY Change 30.39% 20.75%
SHAREHOLDERS EQUITY
Retained Earnings -$102.0M
YoY Change
Common Stock $149.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.720M $230.0K
YoY Change
Total Liabilities & Shareholders Equity $15.14M $6.690M
YoY Change 126.32% -39.4%

Cashflow Statement

Concept 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$3.736M -$5.242M
YoY Change -28.73% 24.22%
Depreciation, Depletion And Amortization $31.00K $41.00K
YoY Change -24.39% -18.0%
Cash From Operating Activities -$3.850M -$4.140M
YoY Change -7.0% 50.55%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$30.00K
YoY Change 33.33% -25.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$40.00K -$30.00K
YoY Change 33.33% -101.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.820M 330.0K
YoY Change 2875.76% -8.33%
NET CHANGE
Cash From Operating Activities -3.850M -4.140M
Cash From Investing Activities -40.00K -30.00K
Cash From Financing Activities 9.820M 330.0K
Net Change In Cash 5.930M -3.840M
YoY Change -254.43% -3300.0%
FREE CASH FLOW
Cash From Operating Activities -$3.850M -$4.140M
Capital Expenditures -$40.00K -$30.00K
Free Cash Flow -$3.810M -$4.110M
YoY Change -7.3% 51.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 nby Prepaid Deposits
PrepaidDeposits
29000
CY2015Q4 nby Prepaid Deposits
PrepaidDeposits
84000
CY2016Q3 nby Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
12000
CY2015Q4 nby Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
394000
CY2016Q3 nby Area Of Property In Sublease Agreement
AreaOfPropertyInSubleaseAgreement
16465
CY2016Q3 nby Class Of Warrant Or Right Exercise Price Discount From Market Price
ClassOfWarrantOrRightExercisePriceDiscountFromMarketPrice
0.16
nby Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
3000
nby Class Of Warrant Or Right Forfeited During Period Exercise Price
ClassOfWarrantOrRightForfeitedDuringPeriodExercisePrice
78.13
nby Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
3087000
nby Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.91
CY2016Q3 nby Class Of Warrants Or Rights Exercises In Period
ClassOfWarrantsOrRightsExercisesInPeriod
3613261
nby Class Of Warrants Or Rights Exercises In Period
ClassOfWarrantsOrRightsExercisesInPeriod
3613000
CY2012Q4 nby Excess Fair Value Over Proceeds Received From Purchase
ExcessFairValueOverProceedsReceivedFromPurchase
1000000
CY2016Q3 nby Fair Value Of Warrants Transferred To Equity Upon Exercise
FairValueOfWarrantsTransferredToEquityUponExercise
-1594000
nby Fixed Assets Exchanged For Services
FixedAssetsExchangedForServices
279000
nby Fixed Assets Exchanged For Services
FixedAssetsExchangedForServices
nby Gain Loss Due To Change In Fair Value Of Warrant
GainLossDueToChangeInFairValueOfWarrant
-2480000
nby Gain Loss Due To Change In Fair Value Of Warrant
GainLossDueToChangeInFairValueOfWarrant
173000
nby Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
59000
nby Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
15000
CY2012Q1 nby Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
66.50
nby Note Receivable Impairment
NoteReceivableImpairment
91000
nby Note Receivable Impairment
NoteReceivableImpairment
CY2007Q3 nby Number Of Subsidiaries
NumberOfSubsidiaries
2
CY2016Q3 nby Prepaid Outsourced Sales Team
PrepaidOutsourcedSalesTeam
646000
CY2015Q4 nby Prepaid Outsourced Sales Team
PrepaidOutsourcedSalesTeam
CY2016Q3 nby Prepaid Research And Development Services
PrepaidResearchAndDevelopmentServices
140000
CY2015Q4 nby Prepaid Research And Development Services
PrepaidResearchAndDevelopmentServices
CY2016Q3 nby Prepaid Sales Rebate
PrepaidSalesRebate
530000
CY2015Q4 nby Prepaid Sales Rebate
PrepaidSalesRebate
CY2016Q2 nby Private Placement Commission Percentage
PrivatePlacementCommissionPercentage
0.06
CY2016Q3 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
nby Proceeds From Exercise Of Options And Warrants
ProceedsFromExerciseOfOptionsAndWarrants
6571000
nby Proceeds From Exercise Of Options And Warrants
ProceedsFromExerciseOfOptionsAndWarrants
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber
325
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice
27.04
nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm
P6Y73D
CY2015Q4 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
388
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
1502
CY2015Q4 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
32.03
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
8.64
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1691000
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber
1478
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.40
nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y328D
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod
325
CY2016Q3 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue
27.04
nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm
P6Y73D
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
133000
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
20000
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
CY2016Q3 nby Warrants Exercised Commission Paid
WarrantsExercisedCommissionPaid
338000
CY2016Q3 nby Warrants Exercised Commission Percentage
WarrantsExercisedCommissionPercentage
0.06
nby Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
1.91
CY2016Q3 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
2079000
CY2015Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
536000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
387000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2483000
CY2016Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
130000
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
12000
CY2015Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1880000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1980000
CY2016Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
149000
CY2015Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
150000
CY2016Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
299000
CY2015Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
396000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1702000
CY2016Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108592000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85387000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
710000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
221000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1227000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1009000
CY2016Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
14000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
40000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2431000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1359000
CY2016Q3 us-gaap Assets
Assets
15141000
CY2015Q4 us-gaap Assets
Assets
5077000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
14420000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
4527000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9430000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2385000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5429000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3383000
us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7045000
us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2046000
CY2011Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
33.25
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
19.50
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.15
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.19
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.12
CY2016Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3613261
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2039530
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1458000
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
929000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14865507000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3486232000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14865507000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3486232000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
149000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
35000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk and Major Partners</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with three highly-rated, major financial institutions in the United States.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deposits in these banks may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held. </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the three months and nine months ended September 30, 2016, revenues were derived primarily from sales of Avenova directly to doctors through the Company&#x2019;s webstore and to three major distribution partners. During the three months and nine months ended September 30, 2015, revenues were derived primarily from one collaboration partner, service revenues and sales of NeutroPhase. </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2016, 36%, 25% and 17% of accounts receivable were from three major distribution partners. As of December 31, 2015, 41% and 18% of accounts receivable were from two major distribution partners.&nbsp;</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2013Q1 us-gaap Contracts Revenue
ContractsRevenue
313000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
566000
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
269000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1656000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
670000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
248000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
189000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1461000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
170000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1913000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2248000
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31000
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.68
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
449000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
614000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1900000
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
385000
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
424000
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1671000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
270000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2012Q1 us-gaap Fees And Commissions Other
FeesAndCommissionsOther
313000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
232000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2218000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1681000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5131000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5181000
CY2016Q3 us-gaap Gross Profit
GrossProfit
2872000
CY2015Q3 us-gaap Gross Profit
GrossProfit
931000
us-gaap Gross Profit
GrossProfit
6164000
us-gaap Gross Profit
GrossProfit
2076000
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
66000
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
CY2015Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3736000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5240000
CY2016Q3 us-gaap Liabilities
Liabilities
8423000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11501000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14759000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2061000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1057000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1544000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
307000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
956000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-24000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-261000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1001000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
374000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
198000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1433000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1000
us-gaap Interest Paid
InterestPaid
51000
us-gaap Interest Paid
InterestPaid
CY2016Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
392000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
482000
CY2016Q3 us-gaap Inventory Net
InventoryNet
1084000
CY2015Q4 us-gaap Inventory Net
InventoryNet
1345000
CY2016Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
769000
CY2015Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
660000
CY2016Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
77000
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
45000
CY2016Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
248000
CY2016Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
360000
CY2015Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
257000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15141000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
873000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
758000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3728000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4633000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
18564000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12033000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-78000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11441000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14070000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3736000
CY2015Q4 us-gaap Liabilities
Liabilities
10175000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5077000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5242000
us-gaap Net Income Loss
NetIncomeLoss
-11503000
us-gaap Net Income Loss
NetIncomeLoss
-14769000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
20000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
CY2011Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
139520
CY2016Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1655000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
4885000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
6279000
us-gaap Operating Expenses
OperatingExpenses
15006000
us-gaap Operating Expenses
OperatingExpenses
16944000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2013000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5348000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8842000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14868000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
329000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
220000
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
286000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
177000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
439000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155000
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
198000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2016Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-1671000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-2480000
CY2015Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
139000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
173000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-179000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000
CY2016Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
176000
CY2015Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
64000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
249000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
187000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1827000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
261000
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1827000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
261000
CY2016Q3 us-gaap Prepaid Rent
PrepaidRent
196000
CY2015Q4 us-gaap Prepaid Rent
PrepaidRent
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 1.2pt 0pt 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications </div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders&#x2019; equity (deficit).</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13648000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1365000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
CY2016Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11800000
CY2016Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11800000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
12033000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
37000
CY2016Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2016Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6600000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-3736000
CY2015Q3 us-gaap Profit Loss
ProfitLoss
-5242000
us-gaap Profit Loss
ProfitLoss
-11503000
us-gaap Profit Loss
ProfitLoss
-14769000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
678000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2097000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
282000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
395000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3020000
us-gaap Repayments Of Debt
RepaymentsOfDebt
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1563000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1215000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4503000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102023000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90520000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3262000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1136000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
7571000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2559000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
3438000
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1200000
us-gaap Sales Revenue Net
SalesRevenueNet
7820000
us-gaap Sales Revenue Net
SalesRevenueNet
2746000
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2663000
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3035000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8660000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7260000
us-gaap Share Based Compensation
ShareBasedCompensation
889000
us-gaap Share Based Compensation
ShareBasedCompensation
869000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y306D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
36.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1199
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1718000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.71
us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
-185000
us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
-140000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y73D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y328D
CY2016Q3 us-gaap Short Term Investments
ShortTermInvestments
0
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
0
us-gaap Stock Issued1
StockIssued1
7000
us-gaap Stock Issued1
StockIssued1
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1518567
CY2016Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2015Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2800000
CY2016Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6718000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5098000
CY2016Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
512000
CY2015Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
590000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 1.2pt 0pt 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.<div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1450000
CY2016Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1835000
CY2016Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2259000
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2336000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10912616000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2957477000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7480985000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2598052000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10912616
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2957477
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7480985
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2598052
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10912616000
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2957477000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7480985000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2598052000

Files In Submission

Name View Source Status
0001437749-16-041758-index-headers.html Edgar Link pending
0001437749-16-041758-index.html Edgar Link pending
0001437749-16-041758.txt Edgar Link pending
0001437749-16-041758-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nby-20160930.xml Edgar Link completed
nby-20160930.xsd Edgar Link pending
nby-20160930_cal.xml Edgar Link unprocessable
nby-20160930_def.xml Edgar Link unprocessable
nby-20160930_lab.xml Edgar Link unprocessable
nby-20160930_pre.xml Edgar Link unprocessable
nby20160830_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending